Alex Ireland is Associate Director Business Development at Novotech, the leading Asia Pacific centered global biotech CRO. During her tenor, she has worked with 125+ biotech companies on 400+ studies in preparation for their upcoming Ph 1-3 clinical trials. Prior to joining Novotech, she worked for a small biotech company in a variety of business development and operational roles. Alex graduated from Boston University with a Master of Public Health.
Ike Ogbaa, MD is currently the US Medical Affairs Lead for New Products and Integrated Diabetes Care at Sanofi. His current role is to develop the US medical affairs strategy for Sanofi’s pipeline of New Diabetes Drugs, Devices and Digital health Solutions. He has extensive experience throughout the Pharmaceutical value chain in Clinical Pharmacology, Drug Development, Field-based Medical Affairs and Home-Office Medical affairs. He has worked for a CRO, small biotech and 2 large Pharma companies.
Mike McLaughlin, MS, MSEd, RAC, has over 20 years of clinical research experience working in various roles at both small and large pharmaceutical companies and in a variety of CRO environments. Since 2017, he has served as Associate Director, Clinical Operations at Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in medical dermatology
I am the Customer Insight Manager at Screwfix. Prior to that I worked within Supply Chain and Merchandising management across both DIY and Luxury retailers including Argos, Homebase and Fortnum & Mason. I manage the insight research we conduct at Screwfix in understanding why our customers behave as they do. I also gain insight and ideas from our customers to help understand how we maximise our business to continue meeting their needs and improving their experience with us. This is a very exciting time as Customer Insight is looked to more and more to drive businesses forward and my team are very much at the forefront of that for Screwfix
Carla Wilkins has over twenty nine years professional experience as an independent Architectural Lighting Designer. In 1997 Ms. Wilkins was one of the founding partners of Lichtvision where she continues working to expand the traditional boundaries of lighting design to encompass all manner of visual experience. In Lichtvision Design she overviews the Concept and Design Department and provides the design synergies of all three Lichtvision offices Berlin, Hong Kong and London. Carla Wilkins is an active Professional Member of IALD.
Scott Samuel is a strategic and entrepreneurial leader with a multi-disciplinary set of skills, including but not limited to strategic direction; governance; enhancing enterprise value; M&A; corporate finance; tax; capital raising;
and succession. Developing and keeping strong relationships with all stakeholder constituencies has been a focal point of Scott’s career.
Professionally diverse; senior management backgrounds in technology, life science and consulting with profitable exits of two technology companies in 8 years.
Scott and Skura founders drove the successful sale and spin off of Skura Corp in 2008 with the sale of the consulting arm (75 employees) to IMS Health (now IQVIA – IQV (NYSE)).
Scott and Skura founders then built up the software spin out (of IMS Health exit) and Scott sold that to Indegene, Inc., a global health solutions company in 2016.
Holds a Master of Science in Engineering & Management from Linköping University in Sweden. 30 years of experiences within the power and automation industry, abroad assignments in Germany, Ecuador, USA and Denmark. Competences from several roles from engineering, internal auditing, controlling to management positions. Today she is responsible for developing new IoT services for the mining businesses including Virtual, Augmented, Mixed, Extended Reality and Drones. In parallel, an industrial PhD student at Mälardalens University focusing on the subject Energy & Safety Diagnostic for Underground facilities.
Gaëtan Herinckx is a senior investment professional passionate about working with growing businesses having positive impact on societies.
He is Manager at BIO, the Belgian Investment Company for Developing Countries. He oversees BIO’s direct investments SME and Corporate (including Agribusiness). BIO invests in financial institutions, enterprises, infrastructure and funds across Africa, Latin America and Asia with an objective to promote economic and social development.
Gaëtan has been working in sustainable investment field over the last 19 years. He first worked for Candriam Asset Management as Head of Sustainable and Responsible Investment. He then participated to the launch of Sustainable Capital, boutique asset manager focusing on investment in Africa (ex-SA) investments. In 2016, he joined BIO with a focus on providing funding to SME and Corporates.
Mr. Herinckx hold a Msc in Business Engineering (UCL, Louvain-La-Neuve), a post-graduate in Financial risk management (Saint-Louis, Brussels) and an International Management Program – MBA (Stern Business School, New-York)
Mr. Berger joined the UBC team in 2003 and has since served in a range of diverse roles leveraging global capabilities in the execution of peri and post marketing product development programs and Real World Evidence generation. In this role, Mr. Berger supports the development of RWD / RWE architectures and solutions to drive greater insight into the safety profile and value proposition of medicines.
Mr. Berger received his Bachelor’s degree from the University of Kansas, holds the Project Management Professional credential and Six Sigma Green Belt certificate.
